Oskar Hansson, research-leader at MultiPark, recently met with Bill Gates to discuss biomarkers for Alzheimer's disease. MultiPark’s scientists conduct world-leading research in biomarkers for Alzheimer’s disease, led by Professor Oskar Hansson at the memory clinic at Skåne University Hospital. He recently met with Bill Gates to discuss the future possibilities in this field. You met with Bill Gat

https://www.multipark.lu.se/article/multipark-researcher-bill-gates-brussels - 2025-08-27

In a large international research study with 1,300 participants from, among other places, Sweden, the USA, the Netherlands and Australia, PET cameras could detect the presence of the proteins tau and amyloid in the participants' brains. iStock/baranozedem A large study led by Lund University in Sweden has shown that people with Alzheimer's disease can now be identified before they experience any s

https://www.multipark.lu.se/article/alzheimers-disease-can-be-diagnosed-symptoms-emerge - 2025-08-27

Inducible viral vectors can be used to investigate the effect of human alpha synucelin on dopamine release and reuptake inside the rodent brain. Photo: Andreas Heuer's group. MultiPark’s backbone for research interactions is about to be reorganized. The 13 new special interest groups (SIGs) address essential scientific and technological needs and provide opportunities for professional development

https://www.multipark.lu.se/article/brain-circuit-analysis-special-interest-group - 2025-08-27

Roberta Battistella defends her thesis 1 December 2022. The glymphatic system clears waste products from the brain. Roberta Battistella defends her thesis about the role of this system in Parkinson’s disease on December 1. Here, she tells about her time as a Ph.D student in Iben Lundgaards research group at MultiPark. Tell us about your research! “The glymphatic system removes waste products from

https://www.multipark.lu.se/article/glymphatic-system-pd-phd-interview-roberta-battistella - 2025-08-27

A microglia (Image: iStock/slevaneara) The brain's big-eating immune cells can slow down the progression of Alzheimer's disease. This is shown by a study that is now published in Nature Aging. The brain's own immune cells are called microglia and are found in the central nervous system. They are big eaters that kill viruses, damaged cells and infectious agents they come across. It has long been kn

https://www.multipark.lu.se/article/brains-immune-cells-can-be-triggered-slow-down-alzheimers-disease - 2025-08-27

Magnus Lindh-Rengifo defends his thesis 16 December 2022. Walking is probably more cognitively demanding than you think. Magnus Lindh-Rengifo defends his thesis about walking aspects in neurodegenerative disorders on December 16. Read about his experiences as a Ph.D student at MultiPark. Tell us about your research! “Walking capability can be a key feature to being able to participate in meaningfu

https://www.multipark.lu.se/article/walking-neurodegeneration-phd-interview-magnus-lindh-rengifo - 2025-08-27

Foto: iStock/andresr. A new study have identified which blood tests are best at detecting Alzheimer’s disease during the earliest stages, and also another blood test that is optimal for detecting relevant treatment effects. These findings will speed up the development of new therapies that can slow down the disease progression. The article was originally published as a press release from the Sahlg

https://www.multipark.lu.se/article/optimal-blood-tests-development-new-therapies-alzheimers-disease - 2025-08-27

Photo: Johan Wingborg, University of Gothenburg. “Lundensare” Nobel Prize winner Arvid Carlsson (1923-2018) did not receive the prestigious Nobel Prize while living or working in Lund – but he is an alumnus! Carlsson grew up in Lund (which could clearly be heard in his Lund accent) and in 1951 he became a doctor of medicine at Lund University. He was employed as an associate professor of pharmacol

https://www.multipark.lu.se/article/nobel-prize-winner-arvid-carlsson-7-things-you-perhaps-did-not-know-about-him-and-his-research - 2025-08-27

In substantia nigra, neurons expressing Calretinin seem to be more resistant to damage. Photo: Lautaro Belfiori. MultiPark’s new special interest groups (SIGs) address essential scientific and technological needs and provide opportunities for professional development and network formation to our young scientists. One of them focus on molecular signaling. Lautaro Belfiori is the convening person. H

https://www.multipark.lu.se/article/molecular-signaling-neurodegenerative-disorders-special-interest-group - 2025-08-27

Keivan Javanshiri defends his thesis 20 January 2023. Profile photo:Tove Smeds. Keivan Javanshiri’s Ph.D. project explores cardiac and vascular pathologies in Lewy body dementia and Alzheimer's disease. January 20, he defends his thesis. Here, he shares the most important findings and why sudden cardiac arrest is a common cause of death in patients with Lewy body disease. Tell us about your resear

https://www.multipark.lu.se/article/cognitive-disease-beyond-brain-phd-interview-keivan-javanshiri - 2025-08-27

We ended the MultiPark year in December as we started it in January: with a MultiPark Retreat! The December retreat was our first big meeting IRL after the pandemic, and it turned out to be a much appreciated event. Thank you to all participants, and thank you once again to the retreat organizing committee for doing such a great job! 2022 was a year of “reopening”. Like a butterfly spreads its win

https://www.multipark.lu.se/article/multipark-closing-circle-2022-and-looking-forward-2023 - 2025-08-27

Katrine Skovgård defends her thesis 19 January 2023. Katrine Skovgård’s Ph.D. project sheds light on the dysfunctions in the brain through which dopaminergic pharmacotherapies for Parkinson’s disease affect motor behaviors. January 19, she defends her thesis. She explains how better experimental models might improve future translational research on dyskinesia. You presented your research at the Mu

https://www.multipark.lu.se/article/why-dopamine-receptor-type-matters-phd-interview-katrine-skovgard - 2025-08-27

Dopamine-producing neurons that researchers from Lund University have grown in the laboratory from human embryonic stem cells. Photo: Agnete Kirkeby. At the end of October 2022, the Swedish Medical Products Agency gave the go-ahead for a clinical trial of the stem cell-based therapy STEM-PD for the treatment of Parkinson’s disease. The cells, generated from embryonic stem cells, have been in devel

https://www.multipark.lu.se/article/nerve-cells-could-transform-treatment-parkinsons - 2025-08-27

Elna Dickson defends her thesis 17 February 2023. Huntington's disease is known as the "dance disease" due to the patient's characteristic motor symptoms. However, Elna Dickson's Ph.D. project shows that the disease also leads to pathological changes outside the brain. February 17, she defends her thesis about metabolic alterations in Huntington's disease. Now, she shares perspectives on her resea

https://www.multipark.lu.se/article/huntingtons-metabolic-dysfunctions-phd-interview-elna-dickson - 2025-08-27

Tomas Roos defends his thesis 17 February 2023. The aggregation of the protein Amyloid-beta (Abeta) into plaques outside the nerve cells has been recognized in patients with Alzheimer’s disease since 1905. But eliminating the plaques has not helped patients so far. Still, Tomas Roos thinks that Abeta matters, but we may need to focus on the aggregates elsewhere. On February 17, he defends his thes

https://www.multipark.lu.se/article/does-alzheimers-disease-start-inside-neurons-phd-interview-tomas-roos - 2025-08-27

The milestone transplant was performed at Skåne University Hospital in February. On 13th of February, a transplant of stem cell-derived nerve cells was administered to a person with Parkinson’s at Skåne University Hospital, Sweden. The product has been developed by Lund University and it is now being tested in patients for the first time. The transplantation product is generated from embryonic ste

https://www.multipark.lu.se/article/first-patient-receives-milestone-stem-cell-based-transplant-parkinsons-disease - 2025-08-27

With the injectable gel the researchers were able to grow electrodes in living tissue. Here it is tested on a microfabricated circuit. Photo: Thor Balkhed/Linköpings universitet The boundaries between biology and technology are becoming blurred. Researchers at Linköping, Lund, and Gothenburg universities in Sweden have successfully grown electrodes in living tissue using the body’s molecules as tr

https://www.multipark.lu.se/article/electrodes-grown-brain - 2025-08-27

Kajsa Brolin defends her thesis 27 March 2023. Photo: Kennet Ruona Kajsa Brolin explores how our genes and environment affect the risk of developing Parkinson’s disease. March 27, she defends her Ph.D. project partly based on MultiPark’s biobank sample collection. Here, she tells about the newly discovered genetic risk factor that might be specific to people in the southern part of Sweden. And is

https://www.multipark.lu.se/article/genes-and-environment-pd-phd-interview-kajsa-brolin - 2025-08-27

After a decade of protocol development and preparations, MultiPark researchers have finally launched the clinical trial. Recently, dopamine-producing cells generated from embryonic stem cells were transplanted into the first Parkinson's patient at Skåne University Hospital. During the autumn 2022, the Swedish MPA (Läkemedelsverket) approved the clinical STEM-PD study. Several of MultiParks PIs hav

https://www.multipark.lu.se/article/stem-pd-bench-bedside-story-multipark-researchers-0 - 2025-08-27

Looking for the next step in your career? In need of some scientific inspiration? Or are you just curious about what MultiPark´s senior researchers are doing and their professional journey? Listen to MultiPark’s new podcast series “Meet our scientists”! In a newly launched podcast, young MultiPark researchers interview our research group leaders about their academic journey and main scientific foc

https://www.multipark.lu.se/article/meet-our-scientists-new-podcast-young-multipark-researchers - 2025-08-27